DUOSOL WITH 2MMOLL POTASSIUM SOLUTION FOR HAEMOFILTRATION

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

Calcium chloride dihydrate (Electrolyte solution); Glucose monohydrate (Electrolyte solution); Magnesium chloride hexahydrate (Electrolyte solution); Potassium chloride (Electrolyte solution); Sodium chloride (Electrolyte solution); Sodium chloride (Sodium bicarbonate solution); Sodium hydrogen carbonate (Sodium bicarbonate solution)

Available from:

B. BRAUN SINGAPORE PTE LTD

ATC code:

B05ZB

Pharmaceutical form:

SOLUTION, STERILE

Composition:

Calcium chloride dihydrate (Electrolyte solution) 1.98g/1000ml; Glucose monohydrate (Electrolyte solution) 9.90g/1000ml; Magnesium chloride hexahydrate (Electrolyte solution) 0.91g/1000ml; Potassium chloride (Electrolyte solution) 1.34g/1000ml; Sodium chloride (Electrolyte solution) 4.21g/1000ml; Sodium chloride (Sodium bicarbonate solution) 6.18g/1000ml; Sodium hydrogen carbonate (Sodium bicarbonate solution) 3.59g/1000ml

Administration route:

INTRAVENOUS

Prescription type:

Prescription Only

Manufactured by:

B. Braun Avitum AG

Authorization status:

ACTIVE

Authorization date:

2019-08-20

Summary of Product characteristics

DUOSOL WITH 2 MMOL/L POTASSIUM
B. Braun Avitum AG
Schwarzenberger Weg 73-79
34212 Melsungen
Germany
688996_0822_Duosol_2K_SG_CPP-K01.indd 1
688996_0822_Duosol_2K_SG_CPP-K01.indd 1
29.08.2022 14:31:42
29.08.2022 14:31:42
– 2 –
1.
NAME OF THE MEDICINAL PRODUCT
Duosol with 2 mmol/l Potassium solution for haemofiltration
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
COMPOSITION OF THE READY-TO-USE SOLUTION FOR HAEMOFILTRATION
AFTER MIXING:
1000 ml ready-to-use solution for haemofiltration contain [mmol/l]:
Na
+
140
K
+
2.0
Ca
2
+
1.5
Mg
2
+
0.5
Cl
–
111
HCO
3
–
35.0
Glucose anhydrous
5.6 (equiv. to 1.0 g)
Theoretical osmolarity [mOsm/l]
296
pH
7.0–8.0
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM Solution for haemofiltration
Clear and colourless solution, free from visible particles
The solution is free from bacterial endotoxins.
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
The ready-to-use solution is indicated for use in patients with
acute renal failure requiring continuous haemofiltration.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
The use of solutions for haemofiltration in patients with acute
renal failure should be under the direction of a physician with
experience in using such treatment. In acute renal failure,
treatment is carried out for a limited period and is discontinued
when renal function is restored.
Posology
The filtration rate prescribed is dependent on the clinical
status and the body weight of the patient. Unless otherwise
prescribed, a filtration rate of 20–25 ml/kg body weight per hour
is recommended for the removal of metabolic waste products
normally excreted in the urine, depending on the metabolic
condition of the patient. A maximum filtration rate of 75 litre
per day is recommended.
The dose-volume is at the discretion of the physician because
the volume of substitution solution depends on the intensity of
treatment performed and on the amount of fluid to be replaced
in order to achieve fluid balance.
Method of administration
Intravenous use.
The